Northern Trust Corp raised its stake in Juno Therapeutics, Inc. (NASDAQ:JUNO) by 11.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 382,631 shares of the biopharmaceutical company’s stock after acquiring an additional 40,468 shares during the quarter. Northern Trust Corp owned about 0.37% of Juno Therapeutics worth $11,438,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently bought and sold shares of JUNO. Pacad Investment Ltd. acquired a new stake in Juno Therapeutics in the 2nd quarter valued at about $105,000. Leisure Capital Management acquired a new stake in Juno Therapeutics in the 2nd quarter valued at about $255,000. Brighton Jones LLC acquired a new stake in Juno Therapeutics in the 2nd quarter valued at about $260,000. CAPROCK Group Inc. acquired a new stake in Juno Therapeutics in the 2nd quarter valued at about $299,000. Finally, Amalgamated Bank increased its position in Juno Therapeutics by 19.0% in the 2nd quarter. Amalgamated Bank now owns 10,900 shares of the biopharmaceutical company’s stock valued at $326,000 after acquiring an additional 1,741 shares in the last quarter. Hedge funds and other institutional investors own 67.18% of the company’s stock.
In related news, insider Sunil Agarwal sold 7,285 shares of Juno Therapeutics stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $44.76, for a total transaction of $326,076.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard Klausner sold 12,000 shares of Juno Therapeutics stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $30.34, for a total transaction of $364,080.00. Following the transaction, the director now directly owns 788,985 shares in the company, valued at approximately $23,937,804.90. The disclosure for this sale can be found here. Insiders have sold a total of 91,670 shares of company stock worth $3,917,857 in the last three months. 15.26% of the stock is owned by insiders.
Several research analysts have recently issued reports on the stock. Raymond James Financial, Inc. raised their target price on shares of Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a research note on Friday. Cowen and Company reaffirmed a “buy” rating on shares of Juno Therapeutics in a research note on Friday. Maxim Group reaffirmed a “buy” rating and issued a $56.00 target price on shares of Juno Therapeutics in a research note on Thursday. Leerink Swann reaffirmed an “in-line” rating and issued a $56.00 target price (up previously from $34.00) on shares of Juno Therapeutics in a research note on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $64.00 target price (up previously from $42.00) on shares of Juno Therapeutics in a research note on Thursday. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $44.20.
Juno Therapeutics, Inc. (JUNO) opened at $58.48 on Friday. Juno Therapeutics, Inc. has a one year low of $17.52 and a one year high of $61.59. The company has a quick ratio of 5.08, a current ratio of 4.77 and a debt-to-equity ratio of 0.01.
Juno Therapeutics (NASDAQ:JUNO) last released its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter last year, the firm earned ($0.57) EPS. Juno Therapeutics’s quarterly revenue was up 115.4% compared to the same quarter last year. equities research analysts expect that Juno Therapeutics, Inc. will post -3.62 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Northern Trust Corp Boosts Holdings in Juno Therapeutics, Inc. (JUNO)” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/11/05/northern-trust-corp-boosts-holdings-in-juno-therapeutics-inc-juno.html.
Juno Therapeutics Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
What are top analysts saying about Juno Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Juno Therapeutics Inc. and related companies.